UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (date of earliest event reported): April 12, 2016

                                 AMERICANN, INC.
                  --------------------------------------------
             (Exact name of registrant as specified in its charter)


          Delaware                     000-54231                 27-4336843
  ------------------------         ------------------         ----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
  of incorporation)                                          Identification No.)

                          3200 Brighton Blvd., Unit 144
                                Denver, CO 80216
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (303) 862-9000




          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 1.01.  Entry Into a Material Definitive Agreement

Agreements with AQUSCAN Delaware Corp.

     On April 12, 2016 AmeriCann  signed  agreements with AQUSCAN Delaware Corp.
("AQUSCAN").  AQUSCAN is one of eleven  applicants  for a  vertically-integrated
license to  cultivate,  process  and sell  medical  cannabis  in  Delaware.  The
Delaware Division of Public Health is scheduled announce the application results
in August of 2016 and award  licenses  for up to two new  Registered  Compassion
Centers ("RCC").

     AQUSCAN  applied  and was  accepted  as  AmeriCann's  Preferred  Partner in
Delaware  and has  agreed to become  the sole  tenant  in the  planned  Delaware
Medical  Cannabis  Center  ("DMCC") if a RCC license is awarded.  AmeriCann will
build and own the facility.

     The DMCC  project is designed  on 10 acres of  unimproved  land  located in
Garrison Oak  Technology  Park in Dover,  DE. The City of Dover,  which owns the
park,  has  executed a Purchase  and Sale  Agreement  for the  property  that is
contingent  upon an award of a  license.  City  officials  have  been  extremely
supportive  of the  project  and  provided  letters of support  for the  AQUSCAN
application submitted on April 13, 2016.

     According  to the  agreement,  in addition  to building a  state-of-the-art
cultivation  facility  at the DMCC,  AmeriCann  will  purchase  and  renovate an
existing  3,200  square  foot  building  located  in Dover as a secure,  medical
cannabis dispensary.

     Additionally,  AmeriCann  may  provide  AQUSCAN  with  financing  of  up to
$750,000  for a five-year  term at 18%  interest  per annum for working  capital
associated with establishing and maintaining the RCC.

     The  state-of-the-art   sustainable  greenhouse  project  will  consist  of
multiple  planned  phases to allow  AQUSCAN  to  support  the  Delaware  medical
marijuana market as it grows. The first phase of the planned project consists of
27,000 sq. ft. of  cultivation  and  processing  infrastructure.  AmeriCann  can
expand the DMCC to approximately  204,000 sq. ft. for AQUSCAN,  based on patient
demand.

     The DMCC  facility  has been  designed  utilizing  AmeriCann's  proprietary
system  known  as  "Cannopy."  AmeriCann  has  drawn  on  its  team's  extensive
experience in traditional  horticulture,  lean manufacturing,  medical research,
facility construction, regulatory compliance, security, cannabis cultivation and
genetics,  extraction  techniques,  and infused product  development.  AmeriCann
recently   announced   a   similar   greenhouse   cultivation   development   in
Massachusetts-The  Massachusetts Medical Cannabis Center, (MMCC) south of Boston
and has partnered with a licensee there.

     AmeriCann will need to secure significant  capital to acquire the property,
develop the first phase of the DMCC project and fund its loan with AQUSCAN.

                                       2
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: April 20, 2016
                                      AMERICANN, INC.


                                      By:  /s/ Timothy Keogh
                                          --------------------------------------
                                          Timothy Keogh, Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kitem101aquscan4-16.txt", "description": "FORM 8-K ITEM 1.01 AQUSCAN", "secsgml_size_bytes": 5388}]
{"company-data": {"conformed-name": "AmeriCann, Inc.", "cik": "0001508348", "assigned-sic": "8742", "irs-number": "274336843", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54231", "film-number": "161582266"}, "business-address": {"street1": "3200 BRIGHTON BLVD.", "street2": "UNIT 114", "city": "DENVER", "state": "CO", "zip": "80216", "phone": "303-898-9832"}, "mail-address": {"street1": "3200 BRIGHTON BLVD.", "street2": "UNIT 114", "city": "DENVER", "state": "CO", "zip": "80216"}, "former-company": [{"former-conformed-name": "Americann, Inc.", "date-changed": "20140516"}, {"former-conformed-name": "Nevada Health Scan, Inc.", "date-changed": "20101220"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (date of earliest event reported): April 12, 2016

                                 AMERICANN, INC.
                  --------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                     000-54231                 27-4336843
  ------------------------         ------------------         ----------------
(State or other jurisdiction      (Commission File No.)     (IRS Employer
  of incorporation)                                          Identification No.)

                          3200 Brighton Blvd., Unit 144
                                Denver, CO 80216
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (303) 862-9000

          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-14(c) under the
     Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.  Entry Into a Material Definitive Agreement

Agreements with AQUSCAN Delaware Corp.

     On April 12, 2016 AmeriCann  signed  agreements with AQUSCAN Delaware Corp.
("AQUSCAN").  AQUSCAN is one of eleven  applicants  for a  vertically-integrated
license to  cultivate,  process  and sell  medical  cannabis  in  Delaware.  The
Delaware Division of Public Health is scheduled announce the application results
in August of 2016 and award  licenses  for up to two new  Registered  Compassion
Centers ("RCC").

     AQUSCAN  applied  and was  accepted  as  AmeriCann's  Preferred  Partner in
Delaware  and has  agreed to become  the sole  tenant  in the  planned  Delaware
Medical  Cannabis  Center  ("DMCC") if a RCC license is awarded.  AmeriCann will
build and own the facility.

     The DMCC  project is designed  on 10 acres of  unimproved  land  located in
Garrison Oak  Technology  Park in Dover,  DE. The City of Dover,  which owns the
park,  has  executed a Purchase  and Sale  Agreement  for the  property  that is
contingent  upon an award of a  license.  City  officials  have  been  extremely
supportive  of the  project  and  provided  letters of support  for the  AQUSCAN
application submitted on April 13, 2016.

     According  to the  agreement,  in addition  to building a  state-of-the-art
cultivation  facility  at the DMCC,  AmeriCann  will  purchase  and  renovate an
existing  3,200  square  foot  building  located  in Dover as a secure,  medical
cannabis dispensary.

     Additionally,  AmeriCann  may  provide  AQUSCAN  with  financing  of  up to
$750,000  for a five-year  term at 18%  interest  per annum for working  capital
associated with establishing and maintaining the RCC.

     The  state-of-the-art   sustainable  greenhouse  project  will  consist  of
multiple  planned  phases to allow  AQUSCAN  to  support  the  Delaware  medical
marijuana market as it grows. The first phase of the planned project consists of
27,000 sq. ft. of  cultivation  and  processing  infrastructure.  AmeriCann  can
expand the DMCC to approximately  204,000 sq. ft. for AQUSCAN,  based on patient
demand.

     The DMCC  facility  has been  designed  utilizing  AmeriCann's  proprietary
system  known  as  "Cannopy."  AmeriCann  has  drawn  on  its  team's  extensive
experience in traditional  horticulture,  lean manufacturing,  medical research,
facility construction, regulatory compliance, security, cannabis cultivation and
genetics,  extraction  techniques,  and infused product  development.  AmeriCann
recently   announced   a   similar   greenhouse   cultivation   development   in
Massachusetts-The  Massachusetts Medical Cannabis Center, (MMCC) south of Boston
and has partnered with a licensee there.

     AmeriCann will need to secure significant  capital to acquire the property,
develop the first phase of the DMCC project and fund its loan with AQUSCAN.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: April 20, 2016
                                      AMERICANN, INC.

                                      By:  /s/ Timothy Keogh
                                          --------------------------------------
                                          Timothy Keogh, Chief Executive Officer